MSA News

“Sticking With MSA” -Dr. Wouter Peelearts (Researcher, Michigan)

Sticking with Multiple System Atrophy

Multiple System Atrophy (MSA) is a rare brain disorder that until recently was largely ignored by the research community. MSA is a rapidly progressing neurodegenerative disease caused by a decline of the body’s most basic and vital functions including breathing, digestion, urination, controlling blood pressure and movement.

MISE À JOUR DES NOUVELLES DE LA RECHERCHE 2022

PROMISING NEW RESEARCH FUNDED 2022

#defeatmsa #kickmsa #MSAresearch #newresearch #MultipleSystemAtrophy #msaunited #Consortium Help Us - Fund Research Now! Choose A Charity in Our Consortium: www.msaunited.org

SUPPORT BLOG: NEED ADVICE? NEED SUPPORT? CALL FOR HELP!

MSA United Research Consortium Advisors

HELP DEFEAT MSA! Donate to A Consortium Partner: Defeat MSA Alliance - USA Defeat MSA/Vaincre AMS Canada Defeat MSA Australia and New Zealand, Ltd. (AU-NZ) Combattiamo AMS/MSA Italia Asociación Española Síndrome Shy Drager – Atrofia Multisistémica * Promising...

“On the Importance of showing up & trying” – By Kimberly Bohannon

Kimberly S. Bohannon was a caregiver to her husband Steve, who passed from MSA at the age of 49. She regularly writes about her experiences in a blog on Medium. Today, for the first time, we share an excerpt from Kimberly’s blog about caring for her husband. Are you...

HAPPY NEW YEAR FROM ALL OF US!

HAPPY NEW YEAR!! May this year increase your hope and happiness! Let’s go forward together to Defeat MSA forever! We thank you for your continued support! www.msacanada.ca/donate-to-us/ #defeatmsa #kickmsa

GIVE THE GIFT OF AWARENESS THIS HOLIDAY!

GIVE AWARENESS FOR THE HOLIDAYS! Help Us Defeat MSA Now! CANADA STORE: https://msacanada.ca/shop/

Lundbeck Launches Phase 2 Study for MSA

Good news from Lundbeck! The company plans to initiate Phase 2 Study for Potential Treatment for Multiple System Atrophy! --- Press Release (Mon, Nov 08, 2021 09:00 CET) H. Lundbeck A/S (Lundbeck), announces that it has expanded its clinical-stage pipeline and is...

Alterity reports additional support for ATH 434

ALTERITY PRESS RELEASE: MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 4 November 2021: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative...

« Older Entries

LOOKING FOR OTHER WAYS TO GET INVOLVED?

LEARN MORE

JOIN THE MOVEMENT TO #DEFEATMSA

SUBSCRIBE TO OUR NEWSLETTER

Copyright: ©2023-2024; Defeat MSA Alliance, All rights reserved. The brand names “Defeat MSA” and “Defeat Multiple System Atrophy” are trademarked and wholly
owned by Defeat MSA Alliance. No part of this website may be copied without the express permission of Defeat MSA Alliance. For information, contact the trademark
and copyright holder: copyright@defeatmsa.org
Privacy Policy

MSA News

About Us

Resources & Downloads

Supporters

Get Involved